@AlexLJanin

@WSJ pharma reporter, @Bagehots fellow '25-26. Signal: ajanin.777

 New York, NY
wsj.com/news/author/alex-janin
Joined March 2013
  • Tweets1.7K
  • Following3K
  • Followers10.4K
187Media
Words of affirmation
6
25
5,495
A patient in Bristol Myers Squibb’s multiple sclerosis study died after taking its experimental cell therapy, the company said Friday. The stock fell 2.4%. wsj.com/livecoverage/stock-m… via @wsj

Patient Death Reported in Bristol Myers Squibb Autoimmune Study

A patient in Bristol Myers Squibb’s multiple sclerosis study died after taking its experimental cell therapy, the company said Friday. The stock fell 2.4%. The patient who died started having...

wsj.com
2
342
A wild October surprise. w/ @LizzyLaw_
6
3
1
10
1,227
EXCLUSIVE - Top RFK Jr. ally and adviser Calley Means has quit the Trump administration. Means was frustrated by White House delays of some of Kennedy’s popular food policies and blamed others in the administration for allowing food companies and special interests to have too much sway, people familiar with the matter said. One of them described him as “disillusioned.” wsj.com/politics/policy/call…

Exclusive | Calley Means, a Top RFK Jr. Adviser, Quits Trump Administration

Means was frustrated by a White House slowdown in policymaking to encourage healthy eating.

wsj.com
62
187
37
693
210,833
Medicaid data show some private-equity-backed chains billed far more hours than rivals. Companies say patient needs guide treatment. on.wsj.com/4z4imEu

Autism-Therapy Workers Say Big Chains Pressured Them to Boost Treatment Hours

Medicaid data show some private-equity-backed chains billed far more hours than rivals. Companies say patient needs guide treatment.

wsj.com
6
10
11
42,193
Alex Janin retweeted
Lizzy Lawrence@LizzyLaw_Oct 15
NEW: I dug into a new class of drugs called "protein degraders" that pharma companies are pouring billions of dollars into, hoping to find a new tool to attack diseases from cancer to Parkinson’s. wsj.com/health/pharma/big-ph…

Big Pharma Is Pouring Billions Into a New Class of ‘Protein Degrader’ Drugs

New medications are showing promise in going after a certain kind of hard-to-target protein in diseased cells.

wsj.com
4
20
1,062
Alex Janin retweeted
Gary Ruskin
@garyruskinOct 9
"Gifts, payments, free meals, and other marketing ploys by pharmaceutical companies heavily influence doctors to prescribe more drugs, choose less appropriate treatments, and drive up prescription costs, according to a systematic review of 93 studies." usrtk.org/healthwire/drug-co…

Drug company gifts, meals, and payments to doctors lead to worse prescribing, review of 93 studies...

Doctors who accept drug company gifts, payments and meals prescribe less appropriately and at higher cost, a new Cochrane review of 93 studies finds.

usrtk.org
4
14
3
21
2,572
Shares of Johnson & Johnson dropped more than 5% Tuesday morning after the company reported weaker-than-expected results from its medical devices division. wsj.com/livecoverage/stock-m… via @wsj

Johnson & Johnson Stock Slides After MedTech Miss

Shares of Johnson & Johnson dropped more than 5% Tuesday morning after the company reported weaker-than-expected results from its medical devices division. “We are clear on where MedTech performance...

wsj.com
1
247
NEW: $JNJ is leaning toward spinning off its orthopedics unit. wsj.com/business/earnings/j-…

J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business

Johnson & Johnson is “leaning” toward spinning out the hips-and-knees business that the company has been looking to hive off, Chief Financial Officer Joseph Wolk said.

wsj.com
229
Alex Janin retweeted
Andrew Kaczynski
@KFILEOct 9
Crazy WSJ data. Between 2022 and 2025, wealth increased 37% for Americans 75 and older, while **decreased** 23% for people under 35. wsj.com/economy/affluent-and…

Affluent and Older Americans Got Much Richer in Postpandemic Years

A Federal Reserve study found overall median net worth rose 2% between 2022 and 2025.

wsj.com
129
946
150
4,178
425,221
Alex Janin retweeted
Liz Essley Whyte
@l_e_whyteOct 8
Context for this HHS inquiry ⬇️ “Kennedy, who for many years worked as an environmental lawyer, successfully petitioned a federal court in 2020 to force the Federal Communications Commission to review its wireless-radiation rules.” wsj.com/health/rfk-jr-s-heal…

Exclusive | RFK Jr.’s Health Department Quietly Removes Webpages Saying Cellphones Aren’t Dangerous

The Department of Health and Human Services undertakes a study on the health effects of cellphones.

wsj.com
HHS
@HHSGovOct 8
What should we know about wireless exposure? HHS is seeking public input and scientific evidence on electromagnetic fields, radiofrequency radiation, and potential health effects — including questions about 5G, Wi-Fi, and wireless infrastructure. Share your input through our Request for Information (RFI) by October 21: regulations.gov/commenton/HH…
2
3
1
8
3,100
Alex Janin retweeted
Hims House
@himshouseOct 8
$LLY $NVO $HIMS 🚨 BREAKING: ELI LILLY $LLY SUES 5 MORE COMPANIES FOR MAKING COPYCAT RETATRUTIDE - American Peptides LLC - LiveWell Peptides - Cenexa Labs LLC - Medrein Health & Aesthetics - Medshape Weight Loss Clinic LLC This follows 6 lawsuits Lilly filed in August against peptide companies
14
16
7
183
79,289
Interesting to see @novonordisk and other pharmas start to investigate GLP-1s in the context of specific longevity markers like biological age. I first wrote about the potential effects of these drugs on aging last March: wsj.com/health/wellness/ozem…

Ozempic’s New Frontier: The War on Aging

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

wsj.com
Eric Topol
@EricTopolOct 7
Semaglutide (Ozempic) consistently reduced proteomic organ age 2-4 years for the heart, artery, and kidney clocks across 5 placebo-controlled trials researchsquare.com/article/r…
1
2
7
895
Alex Janin retweeted
Scott Isaacs
@scottisaacsmdOct 6
Annual prevalence of GLP-1 RA prescriptions without documentation of a US FDA-approved indication. onlinelibrary.wiley.com/doi/…
6
2
37
4,907
Alex Janin retweeted
Lizzy Lawrence@LizzyLaw_Oct 3
Tennessee's failed execution of Christa Pike has resulted in fresh scrutiny of the shaky and secretive supply chain for lethal injection drugs. W/ @AlexLJanin: wsj.com/health/pharma/botche…

Botched Tennessee Execution Draws Scrutiny of Lethal Injection Drugs

U.S. states’ methods for obtaining the drugs used in carrying out executions are shrouded in secrecy.

wsj.com
5
7
1,587
My latest: For as long as drugmakers have been testing weight-loss drugs, the question has been: How much weight do people lose? Now it is changing to: What kind of weight are they losing?
The Wall Street Journal
@WSJOct 1
Drugmakers are targeting muscle preservation and fat loss as they build the next generation of weight-loss medications. on.wsj.com/3Vd54GL

The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind

Drugmakers are targeting muscle preservation and fat loss as they build the next generation of weight-loss medications.

wsj.com
8
540
Alex Janin retweeted
Liz Essley Whyte
@l_e_whyteOct 1
NEW with @LizzyLaw_: The Trump administration is rolling out a program aimed at getting Medicare to match drug prices in other countries for certain high-cost drugs Pharma companies that cut deals with the admin expected to be exempt wsj.com/health/pharma/trump-…

Trump Administration Finalizes Plan to Lower Drug Prices in Medicare

The program to tie U.S. drug costs to prices in other nations is less ambitious than initially proposed after deals with drugmakers.

wsj.com
5
1
6
1,634
NEW: A next-generation weight-loss drug from Eli Lilly, when combined with Zepbound, helped people lose substantially more weight than Zepbound alone, according to a new study wsj.com/health/pharma/lillys… via @WSJ

Lilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study

A drug combination studied in people with Type 2 diabetes lowered blood sugar and helped people lose more weight than with Zepbound alone.

wsj.com
3
5
2
728
The combo of eloralintide (investigational) + Zepbound led patients on the highest dose to lose an average of 23.3% of their body weight over roughly 11 months. Those on Zepbound alone lost an average of 14.8% of their weight.
1
146
Between 11% and 27% of patients on the drug combination dropped out due to side effects, the company said, declining to give more specifics about which dose or doses had higher dropout rates.
60
Hello from the MAHA Summit. A number of reporters denied credentials despite empty press seats. A security guard first said he needed to escort me everywhere but now has given up I guess.
10
47
4
196
19,037
Load more